Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients

Thrombosis and Haemostasis

Volumn 114, Issue 2, 2015, Pages 289-296

  Véricel, Evelyne ^a   Colas, Romain ^a   Calzada, Catherine ^a   Lê, Quang Huy ^a   Feugier, Nathalie ^b   Cugnet, Christine ^c   Vidal, Hubert ^a   Laville, Martine ^a,b   Moulin, Philippe ^a,c   Lagarde, Michel ^a  

^a UNIVERSITÉ LYON 1   (France)

^b Univ Lyon   (France)

^c LOUIS PRADEL HOSPITAL   (France)

Author keywords

Arachidonic acid; Isoprostane; Plasma and platelet lipid composition; Platelet aggregation; Vitamin E

Indexed keywords

11 OXOTHROMBOXANE B2; ALPHA TOCOPHEROL; BUTYLCRESOL; CHOLESTEROL; COLLAGEN; CREATININE; DOCOSAHEXAENOIC ACID; FATTY ACID ESTER; HIGH DENSITY LIPOPROTEIN; ISOPROSTANE DERIVATIVE; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE; PLACEBO; THROMBOXANE B2; TRIACYLGLYCEROL; 11-DEHYDRO-THROMBOXANE B2; 8-EPI-PROSTAGLANDIN F2ALPHA; ANTIOXIDANT; ARACHIDONIC ACID; FATTY ACID; LIPID; MEMBRANE LIPID; PROSTAGLANDIN F2 ALPHA;

ADULT; ARACHIDONIC ACID METABOLISM; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FLUOROMETRY; GAS CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; LIPID COMPOSITION; LIPID PEROXIDATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; THIN LAYER CHROMATOGRAPHY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; URINALYSIS; ANALOGS AND DERIVATIVES; BLOOD; CHEMISTRY; CROSSOVER PROCEDURE; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENT; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; THROMBOCYTE; URINE;

ADMINISTRATION, ORAL; ALPHA-TOCOPHEROL; ANTIOXIDANTS; ARACHIDONIC ACID; BLOOD PLATELETS; COLLAGEN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIETARY SUPPLEMENTS; DINOPROST; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; F2-ISOPROSTANES; FATTY ACIDS; FEMALE; HUMANS; LIPID PEROXIDATION; LIPIDS; MEMBRANE LIPIDS; MIDDLE AGED; OXIDATIVE STRESS; PHOSPHOLIPIDS; PLATELET AGGREGATION; POSTMENOPAUSE; THROMBOXANE B2;

EID: 84939469590     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-12-1003     Document Type: Article

References (40)

1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014; 103: 137-149.
2. Barr ELM, Zimmet PZ, Welborn TA, et al. Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007; 116: 151-157.
3. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: A new perspective in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
4. Zatalia SR, Sanusi H. The role of antioxidants in the pathophysiology, complications, and management of diabetes mellitus. Acta Mad Indonses 2013; 45: 141-147.
5. Hamberg M, Svensson J, Samuelsson B. Thromboxanes : a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci 1975; 72: 2994-2998.
6. Véricel E, Januel C, Carreras M, et al. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status. Diabetes 2004; 53: 1046-1051.
7. Feskens EJ, Virtanen SM, Rasanen L, et al. Dietary factors determining diabetes and impaired glucose tolerance: a 20-year follow-up of the Finnish and Dutch cohorts of the Seven Countries Study. Diabetes Care 1995; 18: 1104-1112.
8. De Caterina R, Madonna R, Bertolotto A, et al. N-3 fatty acids in the treatment of diabetic patients. Diabetes Care 2007; 30: 1012-1026.
9. Gao LG, Cao J, Mao QX, et al. Influence of omega-3 polyunsaturated fatty acidsupplementation on platelet aggregation in humans: a meta-analysis of randomized controlled trials. Atherosclerosis 2013; 226: 328-334.
10. Erkkilä AT, Matthan NR, Herrington DM, et al. Higher plasma docosahexaenoic acid is associated reduced progression of coronary atherosclerosis in women with CAD. J Lipid Res 2006; 47: 2814-2819.
11. Sacks FM, Stone PH, Gibson CM, et al. (HARP Research Group). Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol 1995; 25: 1492-1498.
12. Yagi K. Lipid peroxides and human diseases. Chem Phys lipids 1987; 45: 337-351.
13. Véricel E, Polette A, Bacot S, et al. Pro- and antioxidant activities of docosahexaenoic acid on human blood platelets. J thromb Haemost 2003; 13: 566-572.
14. Guillot N, Caillet E, Laville M, et al. Increasing intakes of the long-chain omega-3 docosahexaenoic acid: effects on platelet functions and redox status in healthy men. FASEB J 2009; 23: 2909-2916.
15. Lagarde M, Bryon PA, Guichardant M, et al. A simple and efficient method for platelet isolation from their plasma. Thromb Res 1980; 17: 581-588.
16. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
17. Boukhchache D, Lagarde M. Interactions between prostaglandin precursors during their oxygenation by human platelets. Biochim Biophys Acta 1982; 713: 386-392.
18. Croset M, Véricel E, Rigaud M, et al. Functions and tocopherol content of blood platelets from elderly people after low intake of purified eicosapentaenoic acid. Thromb Res 1990; 57: 1-12.
19. Therasse J, Lemonnier F. Determination of plasma lipoperoxides by high performance liquid chromatography. J Chromatogr 1987; 413: 237-241.
20. Bowyer DE, Leat WM, Howard AN, et al. The determination of the fatty acid composition of serum lipids separated by thin-layer chromatography; and a comparison with column chromatography. Biochim Biophys Acta 1963; 70: 423-431.
21. Woodman RJ, Mori TA, Burke V, et al. Effects of purified eicosapentaenoic acid on platelet, fibrinolytic and vascular function in hypertensive type 2 diabetic patients. Atherosclerosis 2003; 166: 85-93.
22. Venkatakrishnan P, Anuradha S, Bhattacharjee J, et al. Effects of low dose of omega-3 fatty acids on platelet functions and coagulation profile in Indian patients with type 2 diabetes mellitus with vascular complications : a prospective, preliminary study. J Indian Acad Clin Med 2007; 8: 45-52.
23. Corey EJ, Shih C, Cashman JR. Docosahexaenoic acid is a strong of prostaglandin but not leukotriene biosynthesis. Proc Natl Acad Sci 1983; 80: 3581-3584.
24. Catella F, Healy D, Lawson S, et al. 11-dehydro-thromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sci USA 1986; 83: 5861-5865.
25. Davì G, Chiarelli F, Santilli F, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107: 3199-3203.
26. Kesavulu MM, Kameswararao B, Apparao Ch, et al. Effect of omega-3 fatty acids on lipid peroxidation and antioxidant enzyme status in type 2 diabetic patients. Diabetes Metab 2002; 28: 20-26.
27. Azizi-Soleiman F, Jazayeri S, Eghtesadi S. Effects of pure eicosapentaenoic and docosahexaenoic acids on oxidative stress, inflammation and body fat mass in patients with type 2 diabetes. Int J Prev Med 2013; 8: 922-928.
28. Praticò D. F(2)-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999; 147:1-10.
29. Mori TA, Woodman RJ, Burke V, et al. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects. Free Radic Biol Med 2003; 35: 772-781.
30. McDonald DM, O’Kane F, McConville M, et al. Platelet redox balance in diabetic patients with hypertension improved by n-3 fatty acids. Diabetes Care 2013; 36: 998-1005.
31. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, et al. Relationships between plasma measures of oxidative stress and metabolic control in NIDDM. Diabetologia 1997; 40: 647-653.
32. Pirillo A, Catapano AL. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Atheroscler Suppl 2013; 14: 237-242.
33. Hartweg J, Farmer AJ, Perera R, and et al. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. Diabetologia 2007; 50: 1593-1602.
34. von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest 1985; 76: 2446-2450.
35. Conquer JA, Holub BJ. Supplementation with an algae source of docosahexaenoic acid increases (n-3) fatty acid status and alters selected risk factors for heart disease in vegetarian subjects. J Nutr 1996; 12: 3032-3039.
36. Conquer JA, Holub BJ. Dietary docosahexaenoic acid as a source of eicosapentaenoic acid in vegetarians and omnivores. Lipids 1997; 32: 341-345.
37. Shaikh SR, Kinnun JJ, Leng X, et al. How polyunsaturated fatty acids modify molecular organization in membranes: Insight from NMR studies of model systems. Biochim Biophys Acta 2014; Epub ahead of print.
38. Jump DB, Botolin D, Wang Y, et al. Fatty acid regulation of hepatic gene transcription. J Nutr 2005; 135: 2503-2506.
39. Mukherjee PK, Marcheselli VL, Serhan CN, et al. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci 2004;101: 8491-8496.
40. Chen P, Véricel E, Lagarde M, et al. Poxytrins, a class of oxygenated products from polyunsaturated fatty acids, potently inhibit blood platelet aggregation. FASEB J 2011; 25: 382-388.